Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Apr 16, 2026, 16:10Hamid Noori: Etiological Classification of Anemia Understanding the Root Cause
-
Apr 16, 2026, 15:29Sebastian Klapa: Key Findings On Mortality And Cardiovascular Risk In ANCA-Associated Vasculitis
-
Apr 16, 2026, 15:23Ifeanyichukwu Ifechidere: Argatroban – Its ‘Rescue Mission’ in Heparin-Induced Thrombocytopenia
-
Apr 16, 2026, 14:58When Early Diagnosis Is the First Step in Hemophilia A Care – WFH
-
Apr 16, 2026, 14:05Saleh Shamse Basha: When Platelet Counts Mislead, The PLT-F Becomes Critical
-
Apr 16, 2026, 13:44Maha Othman: Celebrating National Medical Laboratory Week in Canada
-
Apr 16, 2026, 13:42Megan Adediran: How Much of What You Know About Hemophilia Is True?
-
Apr 16, 2026, 13:35Priya Singh: How to Write the Discussion of a Research Paper
-
Apr 16, 2026, 13:14Veronica Sanchez: Blood Pressure Categories for Individuals Who Are Pregnant